Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a)
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Aims: Elevated lipoprotein(a) [Lp(a)] is strongly associated with an increased cardiovascular disease (CVD) risk. We previously reported that pro-inflammatory activation of circulating monocytes is a potential mechanism by which Lp(a) mediates CVD. Since potent Lp(a)-lowering therapies are emerging, it is of interest whether patients with elevated Lp(a) experience beneficial anti-inflammatory effects following large reductions in Lp(a). Methods and results: Using transcriptome analysis, we show that circulating monocytes of healthy individuals with elevated Lp(a), as well as CVD patients with increased Lp(a) levels, both have a pro-inflammatory gene expression profile. The effect of Lp(a)-lowering on gene expression and function of monocytes was addressed in two local sub-studies, including 14 CVD patients with elevated Lp(a) who received apolipoprotein(a) [apo(a)] antisense (AKCEA-APO(a)-LRx) (NCT03070782), as well as 18 patients with elevated Lp(a) who received proprotein convertase subtilisin/kexin type 9 antibody (PCSK9ab) treatment (NCT02729025). AKCEA-APO(a)-LRx lowered Lp(a) by 47% and reduced the pro-inflammatory gene expression in monocytes of CVD patients with elevated Lp(a), which coincided with a functional reduction in transendothelial migration capacity of monocytes ex vivo (−17%, P < 0.001). In contrast, PCSK9ab treatment lowered Lp(a) by 16% and did not alter transcriptome nor functional properties of monocytes, despite an additional reduction of 65% in low-density lipoprotein cholesterol (LDL-C). Conclusion: Potent Lp(a)-lowering following AKCEA-APO(a)-LRx, but not modest Lp(a)-lowering combined with LDL-C reduction following PCSK9ab treatment, reduced the pro-inflammatory state of circulating monocytes in patients with elevated Lp(a). These ex vivo data support a beneficial effect of large Lp(a) reductions in patients with elevated Lp(a).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671 · cited 1×
“Epidemiological and Mendelian randomization studies suggest an independent and causal relationship between elevated Lp(a) levels (above 50 mg/dL or 125 nmol/L) and CVD risk.(2,3) Previously, we demonstrated that healthy subjects with elevated Lp(a) have an activated innate immune system, characterized by pro-inflammat…”
BackgroundEffects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357 · cited 1×
“Epidemiological and Mendelian randomization studies suggest an independent and causal relationship between elevated Lp(a) levels (above 50 mg/dL or 125 nmol/L) and CVD risk.(2,3) Previously, we demonstrated that healthy subjects with elevated Lp(a) have an activated innate immune system, characterized by pro-inflammat…”
BackgroundImai, Y., Kuba, K., Neely, G. G., Yaghubian-Malhami, R., Perkmann, T., van Loo, G., Ermolaeva, M., Veldhuizen, R., Leung, Y. H. C., Wang, H., et al. (2008) · Cell · doi:10.1016/j.cell.2008.02.043 · Cited by 1,356
A Test in Context: Lipoprotein(a)
Tsimikas, S. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.042 · Cited by 1,137 · cited 1×
“Lipoprotein(a) [Lp(a)] is a lipoprotein consisting of a low-density lipoprotein (LDL)-like particle, covalently bound to apolipoprotein(a) [apo(a)] and is associated with cardiovascular disease (CVD) risk.(1)”
BackgroundSelf-citationLipoprotein(a) Reduction in Persons with Cardiovascular Disease
Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., Tardif, J.-C., Baum, S. J., Steinhagen-Thiessen, E., Shapiro, M. D., Stroes, E. S., Moriarty, P. M., Nordestgaard, B. G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1905239 · Cited by 1,094 · cited 2×
“These results were generally comparable with the main phase-2b trial.(10) The 18 subjects participating in the ANITSCHKOW trial received monthly subcutaneous injections of evolocumab 420 mg, reaching a mean absolute reduction in Lp(a) of 19 (20) mg/dL [or 48 (49) nmol/ L] and a mean percent reduction of 16 (19) % (Tab…”
MethodResultSelf-citationEffects of anacetrapib in patients with atherosclerotic vascular disease
The HPS3/TIMI55–REVEAL Collaborative Group (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706444 · Cited by 1,047
Viney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754
Self-citation
Cited by
Reyes-Soffer, G., Ginsberg, H. N., Berglund, L., Duell, P. B., Heffron, S. P., Kamstrup, P. R., Lloyd-Jones, D. M., Marcovina, S. M., Yeang, C., Koschinsky, M. L., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000147 · Cited by 836
The dawn of a new era of targeted lipid-lowering therapies
Tokgözoğlu, L., & Libby, P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab841 · Cited by 171
Hepatocyte targeting via the asialoglycoprotein receptor
Ramírez-Cortés, F., & Ménová, P. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00652f · Cited by 55
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
Metadata
- Authors
- Stiekema, L. C. A., Prange, K. H. M., Hoogeveen, R. M., Verweij, S. L., Kroon, J., Schnitzler, J. G., Dzobo, K. E., Cupido, A. J., Tsimikas, S., Stroes, E. S. G., de Winther, M. P. J., & Bahjat, M.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-04-08
- Volume
- 41
- Issue
- 24
- Pages
- 2262-2271
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W3014969146
- Cited by
- 118
- References
- 13
- FWCI
- 12.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a). https://app.cochat.ai/papers/10.1093/eurheartj/ehaa171
- The paper
- Stiekema, L. C. A., Prange, K. H. M., Hoogeveen, R. M., Verweij, S. L., Kroon, J., Schnitzler, J. G., Dzobo, K. E., Cupido, A. J., Tsimikas, S., Stroes, E. S. G., de Winther, M. P. J., & Bahjat, M. (2020). Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a). European Heart Journal. https://doi.org/10.1093/eurheartj/ehaa171
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.